Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Aura Biosciences Inc (AURA)

Aura Biosciences Inc (AURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights Business Wire - Wed Mar 15, 2023

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial...

AURA : 7.89 (+1.54%)
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration Business Wire - Thu Feb 16, 2023

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 7.89 (+1.54%)
Why Shares of Aura Biosciences Jumped This Week Motley Fool - Fri Feb 10, 2023

The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.

AURA : 7.89 (+1.54%)
Aura Biosciences to Participate in Upcoming Investor Conferences Business Wire - Thu Feb 9, 2023

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that...

AURA : 7.89 (+1.54%)
Aura Biosciences Announces Pricing of Public Offering of Common Stock Business Wire - Wed Nov 30, 2022

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 7.89 (+1.54%)
Aura Biosciences Announces Proposed Public Offering of Common Stock Business Wire - Wed Nov 30, 2022

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 7.89 (+1.54%)
Aurora set for major expansion after SET debut, first for jewel retail biz ACN Newswire - Tue Nov 29, 2022

BANGKOK, Nov 29, 2022 - (ACN Newswire) - Aurora Design PCL (SET: AURA), one of Thailand's leaders in gold jewelry retail business, diamond jewelry and gems, is going ahead with its planned expansion after...

AURA : 7.89 (+1.54%)
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Business Wire - Thu Nov 10, 2022

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial...

AURA : 7.89 (+1.54%)
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma Business Wire - Thu Nov 10, 2022

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that...

AURA : 7.89 (+1.54%)
Aura Biosciences to Participate in Upcoming Investor Conferences Business Wire - Thu Nov 3, 2022

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that...

AURA : 7.89 (+1.54%)

Barchart Exclusives

3 High-Yield Dividend Stocks Ready to Soar Barchart - Fri May 3, 6:00PM CDT
These three stocks are cheap, pay a high dividend, and are highly rated. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot